| SPECIES: | SARS-CoV-2 |
| SOURCE SPECIES: | HEK293 cells |
| SEQUENCE: | VNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSG TNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKV CEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQG NFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLAL HRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKC TLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISN CVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKI ADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQA GSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKST NLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQT RAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSAS |
| TESTED APPLICATIONS: | ELISA |
| APPLICATIONS: | ELISA |
Specifications| PURITY: | >95% by SDS Page |
| PREDICTED MOLECULAR WEIGHT: | The predicted molecular mass is ~77 kDa. |
| PHYSICAL STATE: | Liquid |
| BUFFER: | This recombinant protein is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added. |
| CONCENTRATION: | 0.5 mg/ml |
| STORAGE CONDITIONS: | This recombinant protein may be stored as received at 2-8˚C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80˚C. Avoid Repeated Freeze Thaw Cycles. |
| ACCESSION NO.: | QHD43416.1 |
| GENE ID: | 1791269090 |
| BACKGROUND: | The SARS-CoV-2 Spike (S) Protein consists of the S1 and S2 domains. The S1 subunit contains the N-terminal domain (NTD) and receptor-binding domain (RBD). The S1 subunit recognizes and binds to angiotensin-converting enzyme 2 (ACE2) receptors on target cells through the RBD portion, and subsequent conformational changes in S2 allow for fusion between the viral envelope and host cell membrane. SARS-CoV-2 is closely related to the SARS virus, which was first identified in 2002-20031. Both SARS-CoV and SARS-CoV-2 utilize the ACE2 cell receptor to gain entry into cells, with SARS-CoV-2 binding with higher affinity2. Vaccine and therapeutic development are targeting portions of the spike protein, including the S1 portion3. |
| REFERENCES: | 1) Quinlan et al. bioRxiv:2020. | 2) Wrapp et al. Science: 2020. | 3) Tai et al. Nature: 2020. |
FOR RESEARCH USE ONLY.
For additional information, visit ProSci's Terms & Conditions Page.
